Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation

Ido Sadras, Eitan Kerem*, Galit Livnat, Ifat Sarouk, Oded Breuer, Joel Reiter, Alex Gileles-Hillel, Ori Inbar, Michael Cohen, Ayelet Gamliel, Noemie Stanleigh, Tarini Gunawardena, Claire Bartlett, Tanja Gonska, Theo Moraes, Paul D.W. Eckford, Christine E. Bear, Felix Ratjen, Batsheva Kerem, Michael WilschanskiMichal Shteinberg, Malena Cohen-Cymberknoh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology